Exact Mass: 654.2689508000001
Exact Mass Matches: 654.2689508000001
Found 181 metabolites which its exact mass value is equals to given mass value 654.2689508000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Mezerein
Crystals or white powder. (NTP, 1992) Mezerein is a diterpenoid. D009676 - Noxae > D002273 - Carcinogens D000970 - Antineoplastic Agents
Coproporphyrin I
C36H38N4O8 (654.2689508000001)
Coproporphyrin I is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. Coproporphyrin I is a tetrapyrrole dead-end product from the spontaneous oxidation of the methylene bridges of coproporphynogen, arising from heme synthesis and secreted in feces and urine. Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia. Porphyria is a pathological state characterised by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: 1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, 2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, 3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors includes disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss from, and diminished utilization of coproporphyrinogen in the hepatocytes, which may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine; decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion, so that the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function and intrahepatic cholestasis; and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms. (PMID: 3327428). Coproporhyrin I is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life.
Coproporphyrin III
C36H38N4O8 (654.2689508000001)
Coproporphyrin III is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. Coproporphyrin III is a tetrapyrrole dead-end product from the spontaneous oxidation of the methylene bridges of coproporphynogen, arising from heme synthesis and secreted in feces and urine. Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia, which are inherited disorders. Porphyria is a pathological state characterised by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: 1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, 2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, 3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors includes disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss from, and diminished utilization of coproporphyrinogen in the hepatocytes, which may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine; decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion, so that the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function and intrahepatic cholestasis; and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms. (PMID: 3327428). Excreted in small amounts in urine and faeces, found in blood, yeast, microorganisms etc. By-product of Haem formation in vivo, due to oxidation of the porphyrinogen (CCD) Coproporphyrin III (Zincphyrin) is a naturally occurring porphyrin derivative that is mainly found in urine[1][2].
cryptophycin
C35H43ClN2O8 (654.2707788000001)
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
Citbismine F
Citbismine F is found in citrus. Citbismine F is an alkaloid from Citrus paradisi (Marsh grapefruit Alkaloid from Citrus paradisi (Marsh grapefruit). Citbismine F is found in citrus.
Coproporphyrin II
C36H38N4O8 (654.2689508000001)
Coproporphyrin II is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. This is a rare coproporphyrin isomer and it constitues only 1\\% of all coproporphyrins. This isomer appears to arise spontaneously as opposed to enzymatically. Coproporphyrin II is a tetrapyrrole dead-end product from the spontaneous oxidation of the methylene bridges of coproporphynogen, arising from heme synthesis and secreted in feces and urine. Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia. Porphyria is a pathological state characterised by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: 1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, 2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, 3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors includes disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss from, and diminished utilization of coproporphyrinogen in the hepatocytes, which may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine; decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion, so that the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function and intrahepatic cholestasis; and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms. (PMID: 3327428). Coproporhyrin II is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. This is a rare coproporphyrin isomer and it constitues only 1\\% of all coproporphyrins. This isomer appears to arise spontaneously as opposed to enzymatically.
Coproporphyrin IV
C36H38N4O8 (654.2689508000001)
Coproporphyrin IV is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. This is a rare coproporphyrin isomer and it constitues only 2\\% of all coproporphyrins. This isomer appears to arise spontaneously as opposed to enzymatically. Coproporphyrin IV is a tetrapyrrole dead-end product from the spontaneous oxidation of the methylene bridges of coproporphynogen, arising from heme synthesis and secreted in feces and urine. Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia. Porphyria is a pathological state characterised by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: 1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, 2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, 3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors includes disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss from, and diminished utilization of coproporphyrinogen in the hepatocytes, which may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine; decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion, so that the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function and intrahepatic cholestasis; and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms. (PMID: 3327428). Coproporhyrin IV is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. This is a rare coproporphyrin isomer and it constitues only 2\\% of all coproporphyrins. This isomer appears to arise spontaneously as opposed to enzymatically.
Isocoproporphyrin
C36H38N4O8 (654.2689508000001)
Isocoproporphyrin is a porphyrin derivative found in the feces and in urine for patients suffering from PCT (porphyria cutanea tarda). PCT is probably the most common of the porphyrias. It manifests as vesicle formation in sun-exposed areas, particularly the dorsum of the hands, A finding that is virtually diagnostic of PCT is the presence of isocoproporphyrin in stool. A porphyrin derivative found in the feces and in urine for patients suffering from PCT (porphyria cutanea tarda). PCT is probably the most common of the porphyrias. It manifests as vesicle formation in sun-exposed areas, particularly the dorsum of the hands, A finding that is virtually diagnostic of PCT is the presence of isocoproporphyrin in stool [HMDB]
cryptophycin
C35H43ClN2O8 (654.2707788000001)
mezerein
silvestrol
3-Hydroxy-6-desmethylthalifaboramine
C38H42N2O8 (654.2941012000001)
Thiomarinol D
An organosulfur heterocyclic compound produced by a marine bacterium Alteromonas rava and has been shown to exhibit antibacterial activity against Gram-positive and Gram-negative bacteria. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
(2R,3R,4S)-(-)-3alpha-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosylisolariciresinol
??-D-Glucopyranosyl-(1鈥樏傗垎2)-??-D-glucopyranosyl-15,16-epoxy-12-oxo-8(17),13(16)-14-ent-labdatrien-19-oate
(4S)-4,6-dimethyl-2,4,6-tri(5,6-dimethoxy-2-benzofuranyl)-1-heptene|stenocephalin B
(S)-4-(4-hydroxyphenyl)-2-butanol 2-O-[6-O-(3,5-dimethoxy-4-O-alpha-L-rhamnopyranosylgalloyl)-beta-D-glucopyranoside]
3??,5??,8??,15??-Tetraacetoxy-7??-benzoyloxyjatropha-6(17),11E-dien-9,14-dione
(1alpha,6beta,14alpha,16beta)-1,6,14,16-tetramethoxy-4-{{[2-(3-methyl-2,5-dioxopyrrolidin-1-yl)benzoyl]oxy}methyl}aconitane-7,8-diol|N-deethylmethyllylcaconitine
4,5-dioxo-4,5-secopheophorbide b methyl ester
C36H38N4O8 (654.2689508000001)
(7S,8R)-dihydrodehydrodiconiferyl alcohol 9-O-beta-D-apiofuranosyl-(1->6)-O-beta-D-glucopyranoside
13-deacetoxy-13,15-epoxy-11(15-->1)abeo-13-epi-baccatin VI|13-Deacetoxy-13,15-epoxy-11(15鈥樏傗垎1)-abeo-13-epi-baccatin VI
(7R,8S)-dihydrodehydrodiconiferyl alcohol-4-O-alpha-L-rhamnopyranosyl-3-O-beta-D-glucopyranoside
(2S,2S)-2,2-(((1S,2S,3S,4S)-2,4-bis(4-hydroxyphenyl)cyclobutanedicarbonyl)bis(azanediyl))bis(3-(4-hydroxyphenyl)propanoic acid)|abrusamide B
5S-1,7-bis(3,4-dihydroxyphenyl)-5-O-beta-D-(2-O-feruloylxylopyranosyl)heptan-3-one|oregonoyl B
cinnacassoside B|dihydrodehydrodiconiferyl alcohol 9-beta-D-apiofuranosyl-(1?6)-beta-D-glucopyranoside
2alpha,9alpha,10beta-triacetoxy-11,12-epoxytax-4(20)-en-13-one-5alpha-O-beta-D-glucopyranoside
15-O-acetylcheiradone|rel-(2aR,5S,5aS,6S,6aS,7R,8R,9aS,10aR,10bS)-5,7,9a-tris(acetyloxy)-5a-[(acetyloxy)methyl]-6-benzoyloxy-2,2a,5,5a,6,6a,7,8,9,9a,10a,10b-dodecahydro-2,2,8,10a-tetramethyl-10H-azuleno[5,6,7-cd]isobenzofuran-10-one
15-((3aXi,11bR)-8,11c-dihydroxy-3-methyl-6-oxo-(11cc)-2,3,3a,5,6,11c-hexahydro-1H,4H-indolo[3,2,1-de][1,5]naphthyridin-11br-yl)-19-hydroxy-16,17-dimethoxy-1-methyl-3,4-didehydro-aspidospermidin-21-oic acid 19-lactone|Cimiciphytin|cimiciphytine
C37H42N4O7 (654.3053342000001)
(2S,3S,3aR,4R,4aR,5R,8S,8aR,9S,10aR)-3,5,10a-triacetoxy-4a-(acetoxymethyl)-9-hydroxy-2,9-dimethyl-8-(methylethenyl)-10-oxo-1,2,3,3a,4,4a,5,8,8a,9,10,10a-dodecahydrobenzo[f]-azulen-4-yl benzoate|3,7,15,17-O-tetraacetyl-5-O-benzoyl-13-hydroxymyrsinol|isodecipinone
(2S,3S,3aR,4R,4aR,5R,8S,8aR,9S,10aR)-3,5,9-triacetoxy-4a-(acetoxymethyl)-10a-hydroxy-2,9-dimethyl-8-(methylethenyl)-10-oxo-1,2,3,3a,4,4a,5,8,8a,9,10,10a-dodecahydrobenzo[f]-azulen-4-yl benzoate|decipinone
Silvestrol
Silvestrol is an organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity. It has a role as a metabolite and an antineoplastic agent. It is an organic heterotricyclic compound, a member of dioxanes, an ether and a methyl ester. Silvestrol is a natural product found in Aglaia foveolata and Aglaia silvestris with data available. An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.
Coproporphyrin III
C36H38N4O8 (654.2689508000001)
Coproporphyrin III (Zincphyrin) is a naturally occurring porphyrin derivative that is mainly found in urine[1][2].
9,9-di-O-E-p-Coumaroyl-(8R,8R)-secoisolariciresinol
9-O-E-p-Coumaroyl-9-O-Z-p-coumaroyl-(8R,8R)-secoisolariciresinol
9,9-di-O-Z-p-Coumaroyl-(8R,8R)-secoisolariciresinol
Phe Tyr Tyr Tyr
C36H38N4O8 (654.2689508000001)
Met Arg Trp Tyr
Met Arg Tyr Trp
Met Trp Arg Tyr
Met Trp Tyr Arg
Met Tyr Arg Trp
Met Tyr Trp Arg
Arg Met Trp Tyr
Arg Met Tyr Trp
Arg Trp Met Tyr
Arg Trp Tyr Met
Arg Tyr Met Trp
Arg Tyr Trp Met
Thr Trp Trp Tyr
Thr Trp Tyr Trp
Thr Tyr Trp Trp
Trp Met Arg Tyr
Trp Met Tyr Arg
Trp Arg Met Tyr
Trp Arg Tyr Met
Trp Thr Trp Tyr
Trp Thr Tyr Trp
Trp Trp Thr Tyr
Trp Trp Tyr Thr
Trp Tyr Met Arg
Trp Tyr Arg Met
Trp Tyr Thr Trp
Trp Tyr Trp Thr
Tyr Phe Tyr Tyr
C36H38N4O8 (654.2689508000001)
Tyr Met Arg Trp
Tyr Met Trp Arg
Tyr Arg Met Trp
Tyr Arg Trp Met
Tyr Thr Trp Trp
Tyr Trp Met Arg
Tyr Trp Arg Met
Tyr Trp Thr Trp
Tyr Trp Trp Thr
Tyr Tyr Phe Tyr
C36H38N4O8 (654.2689508000001)
Tyr Tyr Tyr Phe
C36H38N4O8 (654.2689508000001)
Citbismine F
(3S)-6,6-DIMETHYL-5-OXOTHIOMORPHOLINE-3-CARBOXYLICACID
TRIISOPROPYL((4-((4-((4-((4-((TRIMETHYLSILYL)ETHYNYL)PHENYL)ETHYNYL)PHENYL)ETHYNYL)PHENYL)ETHYNYL)PHENYL)ETHYNYL)SILANE
Ac-Tyr-Val-Ala-Asp-2,6-dimethylbenzoyloxymethylketone
2-[2-[2-chloro-3-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-1,3,3-trimethylindole,4-methylbenzenesulfonate
C39H43ClN2O3S (654.2682758000001)
1-[(3R)-3-(3,4-dichlorophenyl)-3-[2-(4-phenyl-1-azoniabicyclo[2.2.2]octan-1-yl)ethyl]piperidin-1-yl]-2-(3-propan-2-yloxyphenyl)ethanone chloride
Ccris 4674
D009676 - Noxae > D002273 - Carcinogens D000970 - Antineoplastic Agents
(13E)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[1-(3-phenyloxiran-2-yl)ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
C35H43ClN2O8 (654.2707788000001)
D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents D000890 - Anti-Infective Agents > D000935 - Antifungal Agents
3-[8,13,18-Tris(2-carboxyethyl)-3,7,12,17-tetramethyl-21,23-dihydroporphyrin-2-yl]propanoic acid
C36H38N4O8 (654.2689508000001)
3-(Carboxymethyl)-12-ethyl-8,13,17-trimethyl-21h,23h-porphine-2,7,18-tripropanoic acid
C36H38N4O8 (654.2689508000001)
3,8,12,17-Tetramethyl-2,7,13,18-porphinetetrapropionate
C36H38N4O8 (654.2689508000001)
3-[8,12,18-Tris(2-carboxyethyl)-3,7,13,17-tetramethyl-21,23-dihydroporphyrin-2-yl]propanoic acid
C36H38N4O8 (654.2689508000001)
(Z)-12,13-Bis[(trimethylsilyl)oxy]-9-octadecenoic acid 2-(4-bromophenyl)-2-oxoethyl ester
C32H55BrO5Si2 (654.2771199999999)
(Z)-9,10-Bis[(trimethylsilyl)oxy]-12-octadecenoic acid 2-(4-bromophenyl)-2-oxoethyl ester
C32H55BrO5Si2 (654.2771199999999)
epi-silvestrol
An organic heterotricyclic compound that is a 5-epimer of silvestrol. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.
Z-IETD-FMK
Z-IETD-FMK (Z-IE(OMe)TD(OMe)-FMK) is a selective and cell permeable caspase-8 inhibitor[1]. Z-IETD-FMK is also a granzyme B inhibitor[5].
(11r,26r)-4,5,19,20-tetramethoxy-10,25-dimethyl-2,17-dioxa-10,25-diazaheptacyclo[26.2.2.2¹³,¹⁶.1³,⁷.1¹⁸,²².0¹¹,³⁶.0²⁶,³³]hexatriaconta-1(30),3,5,7(36),13,15,18,20,22(33),28,31,34-dodecaene-6,21-diol
C38H42N2O8 (654.2941012000001)
3-[9,14,19-tris(2-carboxyethyl)-5,10,15,20-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1³,⁶.1⁸,¹¹.1¹³,¹⁶]tetracosa-1,3(24),4,6,8,10,12,14,16,18(21),19-undecaen-4-yl]propanoic acid
C36H38N4O8 (654.2689508000001)
(1r,2s,5r,6r,13s,14s,15s,17s,18s)-6-(furan-3-yl)-17-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-13-yl (2s)-2-methylbutanoate
2-{[8-(4-hydroxy-3-methoxyphenyl)-6-(hydroxymethyl)-3-methoxy-7-{[(3,4,5-trihydroxyoxan-2-yl)oxy]methyl}-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-[(3s)-3-methyl-2,5-dioxopyrrolidin-1-yl]benzoate
(2s,3as,6r,7as)-n-(4-carbamimidamidobutyl)-1-[(2r,3r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl]-6-(sulfooxy)-octahydroindole-2-carboximidic acid
(1s,2r,3r,4s,5r,7s,8r,9r,10r,13r,15r)-2,5-bis(acetyloxy)-4-formyl-13-(furan-3-yl)-9-(2-methoxy-2-oxoethyl)-4,8,10,12-tetramethyl-16-oxatetracyclo[8.6.0.0³,⁸.0¹¹,¹⁵]hexadec-11-en-7-yl (2e)-2-methylbut-2-enoate
n-(4-carbamimidamidobutyl)-1-(2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-methylpentanoyl)-6-(sulfooxy)-octahydroindole-2-carboximidic acid
(1s,2r,5s,6s,13s,14r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-14-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-17-yl (2s)-2-methylbutanoate
(2r,3s,4s,5r,6r)-5-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-6-{[(1r,2s,3s)-7-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl]methoxy}-2-(hydroxymethyl)oxane-3,4-diol
8-{[(2e,4r)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[(2e,4r,5s)-5-hydroxy-4-methylhept-2-en-1-yl]oxan-2-yl]-4-hydroxy-3-methylbut-2-enoyl]oxy}-n-{5-hydroxy-[1,2]dithiolo[4,3-b]pyrrol-6-yl}octanimidic acid
(1s,2r,5s,6s,13s,14r,17r,18s)-6-(furan-3-yl)-13-hydroxy-18-(2-methoxy-2-oxoethyl)-1,5,15-trimethyl-17-[(2-methylpropanoyl)oxy]-8,12-dioxo-7-oxapentacyclo[13.2.1.0²,¹¹.0⁵,¹⁰.0¹³,¹⁷]octadec-10-en-14-yl (2s)-2-methylbutanoate
(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl (1r,4as,5r,8as)-5-[2-(furan-3-yl)-2-oxoethyl]-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylate
(6r)-16-[(2r,5s,6s)-5-(dimethylamino)-6-methyloxan-2-yl]-8-{[(2s,5s,6s)-5-(dimethylamino)-6-methyloxan-2-yl]oxy}-6,15-dihydroxy-6-methyl-2,11-dioxahexacyclo[10.8.0.0¹,³.0³,⁸.0¹⁰,¹².0¹⁴,¹⁹]icosa-14(19),15,17-triene-4,13,20-trione
[2,4,6,8,9-pentakis(acetyloxy)-10-hydroxy-3a-(2-hydroxypropan-2-yl)-1,8a-dimethyl-2h,3h,4h,4ah,5h,6h,7h,8h,9h,10h-cyclohexa[f]azulen-5-yl]methyl acetate
(3s,6r,10s,13e,16s)-10-[(3-chloro-4-methoxyphenyl)methyl]-9,12-dihydroxy-6-methyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadeca-8,11,13-triene-2,5-dione
C35H43ClN2O8 (654.2707788000001)